Sharmilan Thanendrarajan
Concepts (217)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 54 | 2024 | 2915 | 3.910 |
Why?
| Antibodies, Bispecific | 5 | 2024 | 70 | 1.020 |
Why?
| Hematopoietic Stem Cell Transplantation | 8 | 2024 | 554 | 1.010 |
Why?
| Leukemia, Plasma Cell | 2 | 2020 | 33 | 0.880 |
Why?
| Immunotherapy, Adoptive | 5 | 2024 | 158 | 0.730 |
Why?
| Neoplasms, Plasma Cell | 3 | 2024 | 35 | 0.650 |
Why?
| Chromosome Deletion | 2 | 2023 | 138 | 0.590 |
Why?
| Bone Marrow | 9 | 2022 | 351 | 0.580 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 2017 | 35 | 0.570 |
Why?
| Humans | 62 | 2024 | 49898 | 0.560 |
Why?
| Transplantation, Autologous | 9 | 2024 | 462 | 0.540 |
Why?
| Clinical Trials as Topic | 4 | 2022 | 466 | 0.530 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2017 | 213 | 0.500 |
Why?
| Proteasome Inhibitors | 1 | 2016 | 104 | 0.490 |
Why?
| Immunologic Factors | 1 | 2016 | 112 | 0.490 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 4 | 2024 | 111 | 0.490 |
Why?
| B-Cell Maturation Antigen | 6 | 2024 | 88 | 0.480 |
Why?
| Plasma Cells | 5 | 2023 | 221 | 0.470 |
Why?
| Immunotherapy | 1 | 2016 | 235 | 0.450 |
Why?
| Stem Cell Transplantation | 5 | 2024 | 179 | 0.440 |
Why?
| Translocation, Genetic | 5 | 2021 | 263 | 0.440 |
Why?
| Antibodies, Monoclonal | 2 | 2022 | 457 | 0.430 |
Why?
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 824 | 0.420 |
Why?
| Mutation | 6 | 2022 | 1292 | 0.410 |
Why?
| Prognosis | 13 | 2024 | 1956 | 0.400 |
Why?
| Aged | 19 | 2024 | 9447 | 0.400 |
Why?
| Neutropenia | 2 | 2023 | 114 | 0.400 |
Why?
| Survival Analysis | 8 | 2024 | 670 | 0.390 |
Why?
| Neoplasms | 2 | 2012 | 1233 | 0.380 |
Why?
| Cytokine-Induced Killer Cells | 1 | 2011 | 2 | 0.380 |
Why?
| Lymphocytes | 1 | 2012 | 154 | 0.370 |
Why?
| Gene Expression Profiling | 8 | 2023 | 1028 | 0.360 |
Why?
| Cancer Vaccines | 1 | 2011 | 78 | 0.360 |
Why?
| Evolution, Molecular | 2 | 2021 | 97 | 0.360 |
Why?
| Neoplasm, Residual | 5 | 2022 | 156 | 0.350 |
Why?
| Neoplasm Recurrence, Local | 6 | 2024 | 626 | 0.330 |
Why?
| Cytokines | 1 | 2012 | 607 | 0.320 |
Why?
| Tumor Microenvironment | 3 | 2024 | 221 | 0.300 |
Why?
| Hematologic Neoplasms | 2 | 2022 | 98 | 0.290 |
Why?
| Neoplasm Proteins | 3 | 2020 | 321 | 0.290 |
Why?
| Atrial Fibrillation | 2 | 2022 | 182 | 0.280 |
Why?
| Combined Modality Therapy | 4 | 2024 | 638 | 0.280 |
Why?
| Female | 23 | 2024 | 26560 | 0.270 |
Why?
| Middle Aged | 17 | 2024 | 12285 | 0.250 |
Why?
| Aged, 80 and over | 7 | 2024 | 3136 | 0.240 |
Why?
| Fluorodeoxyglucose F18 | 4 | 2021 | 189 | 0.240 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2021 | 46 | 0.230 |
Why?
| Neoplasms, Second Primary | 1 | 2024 | 74 | 0.220 |
Why?
| Treatment Outcome | 8 | 2024 | 5176 | 0.220 |
Why?
| Male | 21 | 2024 | 25437 | 0.220 |
Why?
| Chromosomes, Human, Pair 1 | 2 | 2023 | 92 | 0.210 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 994 | 0.210 |
Why?
| Positron-Emission Tomography | 3 | 2022 | 286 | 0.210 |
Why?
| Adult | 14 | 2024 | 13346 | 0.210 |
Why?
| Risk Factors | 9 | 2024 | 3604 | 0.200 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2020 | 78 | 0.200 |
Why?
| Paraproteinemias | 1 | 2022 | 71 | 0.200 |
Why?
| Immunoconjugates | 1 | 2022 | 38 | 0.200 |
Why?
| Osteolysis | 1 | 2022 | 75 | 0.200 |
Why?
| Drug Approval | 1 | 2022 | 47 | 0.200 |
Why?
| Waldenstrom Macroglobulinemia | 1 | 2022 | 40 | 0.200 |
Why?
| Lymphoma, B-Cell | 1 | 2022 | 61 | 0.190 |
Why?
| Epigenomics | 1 | 2021 | 67 | 0.190 |
Why?
| Patient Participation | 1 | 2022 | 67 | 0.190 |
Why?
| T-Lymphocytes | 4 | 2024 | 328 | 0.190 |
Why?
| Diffusion Magnetic Resonance Imaging | 2 | 2019 | 123 | 0.180 |
Why?
| Genes, Tumor Suppressor | 2 | 2021 | 73 | 0.180 |
Why?
| Cell Cycle | 1 | 2021 | 226 | 0.180 |
Why?
| Practice Guidelines as Topic | 1 | 2023 | 458 | 0.180 |
Why?
| Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.170 |
Why?
| Disease Progression | 5 | 2021 | 820 | 0.170 |
Why?
| Bone Resorption | 1 | 2022 | 297 | 0.170 |
Why?
| Bone Diseases | 1 | 2021 | 97 | 0.170 |
Why?
| Chromosomal Instability | 1 | 2019 | 16 | 0.170 |
Why?
| Gene Regulatory Networks | 1 | 2020 | 107 | 0.170 |
Why?
| Hematopoiesis, Extramedullary | 1 | 2019 | 9 | 0.170 |
Why?
| Antigens, CD | 1 | 2020 | 215 | 0.160 |
Why?
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 10 | 0.160 |
Why?
| Healthcare Disparities | 1 | 2022 | 279 | 0.160 |
Why?
| Spleen | 1 | 2019 | 170 | 0.150 |
Why?
| Spinal Fractures | 1 | 2018 | 37 | 0.150 |
Why?
| Phosphotransferases | 1 | 2018 | 16 | 0.150 |
Why?
| Antineoplastic Agents | 2 | 2024 | 1175 | 0.150 |
Why?
| Bacteremia | 1 | 2019 | 90 | 0.150 |
Why?
| Adipocytes | 1 | 2018 | 121 | 0.150 |
Why?
| Gene Rearrangement | 1 | 2018 | 73 | 0.140 |
Why?
| Recurrence | 4 | 2024 | 658 | 0.140 |
Why?
| Hexokinase | 1 | 2017 | 17 | 0.140 |
Why?
| Epigenesis, Genetic | 1 | 2020 | 370 | 0.140 |
Why?
| Calcification, Physiologic | 1 | 2017 | 40 | 0.140 |
Why?
| Pelvis | 1 | 2017 | 66 | 0.140 |
Why?
| Cell Proliferation | 4 | 2023 | 986 | 0.140 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 103 | 0.140 |
Why?
| Immunoglobulin Light Chains | 1 | 2017 | 82 | 0.140 |
Why?
| Retrospective Studies | 6 | 2024 | 6123 | 0.130 |
Why?
| Clonal Evolution | 1 | 2016 | 56 | 0.130 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 178 | 0.130 |
Why?
| Gene Expression | 1 | 2018 | 612 | 0.130 |
Why?
| Animals | 4 | 2024 | 13100 | 0.120 |
Why?
| Cystatin M | 2 | 2024 | 19 | 0.110 |
Why?
| Cross-Sectional Studies | 3 | 2023 | 1573 | 0.110 |
Why?
| Disease-Free Survival | 3 | 2019 | 450 | 0.100 |
Why?
| Survival Rate | 3 | 2020 | 905 | 0.100 |
Why?
| Cardiovascular Diseases | 1 | 2017 | 444 | 0.100 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2011 | 58 | 0.090 |
Why?
| Mutation Rate | 2 | 2021 | 36 | 0.090 |
Why?
| Disease Models, Animal | 1 | 2016 | 1411 | 0.090 |
Why?
| In Situ Hybridization, Fluorescence | 2 | 2023 | 256 | 0.090 |
Why?
| Alleles | 2 | 2021 | 251 | 0.090 |
Why?
| Genomics | 2 | 2023 | 284 | 0.090 |
Why?
| Tumor Burden | 2 | 2020 | 131 | 0.080 |
Why?
| Histones | 2 | 2021 | 295 | 0.080 |
Why?
| Vaccination | 1 | 2011 | 275 | 0.080 |
Why?
| Transcription Factors | 2 | 2023 | 565 | 0.080 |
Why?
| DNA Copy Number Variations | 2 | 2021 | 108 | 0.080 |
Why?
| Radiopharmaceuticals | 2 | 2021 | 204 | 0.080 |
Why?
| Brain Neoplasms | 1 | 2011 | 282 | 0.080 |
Why?
| Models, Biological | 1 | 2011 | 719 | 0.080 |
Why?
| Cell Differentiation | 2 | 2022 | 649 | 0.070 |
Why?
| Transcriptome | 2 | 2020 | 312 | 0.070 |
Why?
| Follow-Up Studies | 2 | 2024 | 2175 | 0.070 |
Why?
| Kaplan-Meier Estimate | 2 | 2019 | 463 | 0.070 |
Why?
| Imaging, Three-Dimensional | 2 | 2017 | 152 | 0.060 |
Why?
| Biopsy | 2 | 2018 | 591 | 0.060 |
Why?
| Arkansas | 2 | 2021 | 1987 | 0.060 |
Why?
| Killer Cells, Natural | 1 | 2024 | 107 | 0.060 |
Why?
| Ferritins | 1 | 2024 | 30 | 0.060 |
Why?
| Demography | 1 | 2024 | 93 | 0.060 |
Why?
| Myeloid Progenitor Cells | 1 | 2023 | 17 | 0.060 |
Why?
| X-Ray Microtomography | 1 | 2024 | 78 | 0.060 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2024 | 124 | 0.060 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2024 | 53 | 0.060 |
Why?
| Antibodies | 1 | 2024 | 151 | 0.050 |
Why?
| Mice | 2 | 2024 | 5658 | 0.050 |
Why?
| Signal Transduction | 2 | 2021 | 1608 | 0.050 |
Why?
| TNF Receptor-Associated Factor 3 | 1 | 2022 | 13 | 0.050 |
Why?
| Patients | 1 | 2022 | 47 | 0.050 |
Why?
| Geography | 1 | 2022 | 61 | 0.050 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2022 | 33 | 0.050 |
Why?
| Patient Selection | 1 | 2023 | 254 | 0.050 |
Why?
| United States Food and Drug Administration | 1 | 2022 | 91 | 0.050 |
Why?
| Oncogenes | 1 | 2021 | 57 | 0.050 |
Why?
| Bone Marrow Transplantation | 1 | 2022 | 112 | 0.050 |
Why?
| Phylogeny | 1 | 2022 | 234 | 0.050 |
Why?
| Dexamethasone | 1 | 2024 | 424 | 0.050 |
Why?
| Chromosome Aberrations | 1 | 2023 | 295 | 0.050 |
Why?
| Syndecan-1 | 1 | 2021 | 72 | 0.050 |
Why?
| RANK Ligand | 1 | 2022 | 179 | 0.050 |
Why?
| SOXC Transcription Factors | 1 | 2021 | 13 | 0.050 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 84 | 0.050 |
Why?
| Transcriptional Activation | 1 | 2021 | 121 | 0.050 |
Why?
| Chromatin | 1 | 2021 | 137 | 0.050 |
Why?
| Remission Induction | 1 | 2021 | 205 | 0.050 |
Why?
| Clone Cells | 1 | 2021 | 78 | 0.050 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 223 | 0.050 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 66 | 0.050 |
Why?
| Cyclin D2 | 1 | 2020 | 20 | 0.050 |
Why?
| Pyrimidines | 1 | 2022 | 192 | 0.050 |
Why?
| Aneuploidy | 1 | 2020 | 18 | 0.050 |
Why?
| Proto-Oncogene Proteins c-maf | 1 | 2020 | 19 | 0.040 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2020 | 31 | 0.040 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2020 | 31 | 0.040 |
Why?
| Histone Code | 1 | 2020 | 30 | 0.040 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 2020 | 54 | 0.040 |
Why?
| Genome, Human | 1 | 2021 | 110 | 0.040 |
Why?
| Cyclin D1 | 1 | 2020 | 56 | 0.040 |
Why?
| ras Proteins | 1 | 2020 | 65 | 0.040 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2020 | 75 | 0.040 |
Why?
| Protein Kinase Inhibitors | 1 | 2022 | 205 | 0.040 |
Why?
| DNA, Neoplasm | 1 | 2020 | 145 | 0.040 |
Why?
| Health Status Disparities | 1 | 2022 | 196 | 0.040 |
Why?
| Genetic Variation | 1 | 2020 | 215 | 0.040 |
Why?
| DNA Mutational Analysis | 1 | 2020 | 176 | 0.040 |
Why?
| Cell Line, Tumor | 1 | 2023 | 1388 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 168 | 0.040 |
Why?
| Osteoclasts | 1 | 2022 | 424 | 0.040 |
Why?
| Multivariate Analysis | 1 | 2021 | 579 | 0.040 |
Why?
| Computational Biology | 1 | 2020 | 214 | 0.040 |
Why?
| Gram-Positive Bacterial Infections | 1 | 2019 | 27 | 0.040 |
Why?
| Pseudomonas Infections | 1 | 2019 | 47 | 0.040 |
Why?
| Syndrome | 1 | 2019 | 237 | 0.040 |
Why?
| Fractures, Compression | 1 | 2018 | 17 | 0.040 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 424 | 0.040 |
Why?
| Promoter Regions, Genetic | 1 | 2020 | 467 | 0.040 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 51 | 0.040 |
Why?
| Oncogene Proteins, Fusion | 1 | 2018 | 59 | 0.040 |
Why?
| Protein-Tyrosine Kinases | 1 | 2018 | 95 | 0.040 |
Why?
| Kidney Function Tests | 1 | 2017 | 49 | 0.040 |
Why?
| False Positive Reactions | 1 | 2017 | 60 | 0.040 |
Why?
| Bone and Bones | 1 | 2021 | 473 | 0.040 |
Why?
| Glomerular Filtration Rate | 1 | 2017 | 110 | 0.040 |
Why?
| Amino Acid Sequence | 1 | 2018 | 579 | 0.030 |
Why?
| Alkaline Phosphatase | 1 | 2017 | 94 | 0.030 |
Why?
| Genes, ras | 1 | 2016 | 43 | 0.030 |
Why?
| Genes, p53 | 1 | 2016 | 51 | 0.030 |
Why?
| NF-kappa B | 1 | 2018 | 315 | 0.030 |
Why?
| Glycolysis | 1 | 2016 | 68 | 0.030 |
Why?
| DNA Methylation | 1 | 2020 | 544 | 0.030 |
Why?
| Models, Genetic | 1 | 2016 | 174 | 0.030 |
Why?
| Genomic Instability | 1 | 2016 | 91 | 0.030 |
Why?
| Staphylococcal Infections | 1 | 2019 | 269 | 0.030 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2016 | 105 | 0.030 |
Why?
| Logistic Models | 1 | 2018 | 895 | 0.030 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 139 | 0.030 |
Why?
| Heart | 1 | 2017 | 334 | 0.030 |
Why?
| Kidney Diseases | 1 | 2017 | 211 | 0.030 |
Why?
| Algorithms | 1 | 2018 | 613 | 0.030 |
Why?
| Echocardiography | 1 | 2017 | 381 | 0.030 |
Why?
| Time Factors | 1 | 2021 | 2891 | 0.030 |
Why?
| Myocardium | 1 | 2017 | 443 | 0.030 |
Why?
| Disease Management | 1 | 2015 | 175 | 0.030 |
Why?
| Longitudinal Studies | 1 | 2016 | 693 | 0.030 |
Why?
| Risk Assessment | 1 | 2018 | 1254 | 0.030 |
Why?
| Tomography, X-Ray Computed | 1 | 2017 | 1150 | 0.020 |
Why?
| United States | 1 | 2022 | 4878 | 0.020 |
Why?
| Fatal Outcome | 1 | 2011 | 194 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2017 | 1525 | 0.020 |
Why?
|
|
Thanendrarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|